nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2016 | Reply

Reply to Rahbar K et al.

verfasst von: Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Chandrasekhal Bal

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

We appreciate the interest of Rahbar et al. in our recent article “¹⁷⁷Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment” [1]. Rahbar et al. expressed certain reservations and queries concerning our article to which we now respond. …

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3481-7

Schmitz MD, Padula GD, Chun PY, Davis AT. Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer. Radiat Oncol. 2010;5:80. doi:10.1186/1748-717X-5-80.CrossRefPubMedPubMedCentral

Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, et al. Phase-II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2010;107:234–239. doi:10.1111/j.1464-410X.2010.09498.x.CrossRef

Scher HI, Halabi S, Tannock I, Morris M, Strenberg CN, Carducci MA, et al. Design and end points of clinical trials for the patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159. doi:10.1200/JCO.2007.12.4487.CrossRefPubMedPubMedCentral

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–1013. doi:10.2967/jnumed.115.168443.CrossRefPubMed

Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–920. doi:10.2967/jnumed.114.147413.CrossRefPubMed

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–816. doi:10.1007/s00259-012-2330-6.CrossRefPubMedPubMedCentral

Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738–1744.CrossRefPubMed

Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282–3292.CrossRefPubMed

10.

Larson SM, Schwartz LH. 18F-FDG PET as a candidate for “qualified biomarker”: functional assessment of treatment response in oncology. J Nucl Med. 2006;47:901–903.PubMed

11.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–150S.CrossRefPubMedPubMedCentral

12.

Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA-HBED-CC PET/CT detects location and extent of primary prostate cancer. J Nucl Med. 2016. doi:10.2967/jnumed.116.172627

Titel: Reply to Rahbar K et al.
verfasst von: Madhav Prasad Yadav
Sanjana Ballal
Madhavi Tripathi
Chandrasekhal Bal
Publikationsdatum: 01.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3531-1

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma

177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches

Reply

Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy